Douglas Ward, Moti Ramgopal, David J Riedel, Cindy Garris, Shelly Dhir, John Waller, Jenna Roberts, Katie Mycock, Alan Oglesby, Bonnie Collins, Megan Dominguez, James Pike, Joseph Mrus
Background: Dolutegravir-based 2-drug regimens (DTG 2DRs) are now accepted as alternatives to 3-drug regimens for HIV antiretroviral treatment (ART); however, literature on physician drivers for prescribing DTG 2DR is sparse. This study evaluated treatment patterns of DTG 2DR components in clinical practice in the US. Methods: This was a retrospective chart review in adult patients in care in the US with HIV-1 who received DTG 2DR prior to July 31, 2017, with follow-up until January 30, 2018...
2020: AIDS Research and Treatment